ALT
Altimmune, Inc.
$2.61
+0.77%
$507.6M
No data for this timeframe.
Vol
Market Cap$507.6M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (80%)
Inst. Holders50 funds
Inst. Value$174.4M
Inst. Activity19 buys / 6 sells
Insider Activity5B / 0S
Insider Net $$198.4K
Reddit Sentiment33° Cool
SEC Reports10
Press Releases5
Recent Activity
Jun 3, 2026
short_volume
Short Volume: ALT — 58.4% short (1.0M / 1.6M)
Short: 951,954 | Exempt: 0 | TRF Vol: 1,629,206 | Short Ratio: 58.4% | Off-exchange volume (dark poo
May 13, 2026
SEC
Altimmune reported Q1 2026 results with a net loss of $0.18 per share, narrower than the $0.26 loss in Q1 2025, but the
8-K — Impact 4/10
May 13, 2026
SEC
Altimmune reported Q1 2026 EPS of -$0.18, beating the -$0.25 consensus estimate by 28%, though revenue was $0 (vs $1K co
PRESS-RELEASE — Impact 5/10
May 6, 2026
SEC
Altimmune announced it will report Q1 2026 financial results on May 13, 2026. The press release contains no financial re
PRESS-RELEASE — Impact 2/10
May 1, 2026
Insider
SAYARE MITCHEL was granted 48,800 shares
Director
May 1, 2026
Insider
GILL JOHN was granted 48,800 shares
Director
May 1, 2026
Insider
Hodges Philip was granted 48,800 shares
Director
Inst.
BlackRock, Inc. — ADD
12,795,277 shares ($39.4M)
Price Targets
$16.06
+515.2% upside
Strong Buy
Current $2.61
Low $2.50
Median $18.00
High $28.00
9 analysts
$2.50
$28.00
Analyst Ratings
3Strong Buy
9Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 18, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| May 14, 2026 | Citizens | MAINTAIN | Market Outperform → Market Outperform |
| Mar 16, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 6, 2026 | B. Riley Securities | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.16 | $-0.22 — $-0.10 | 41% YoY | 6 |
| Next Q | $-0.18 | $-0.24 — $-0.11 | 16% YoY | 6 |
| Current FY | $-0.74 | $-0.96 — $-0.52 | 26% YoY | 6 |
| Next FY | $-0.90 | $-1.25 — $-0.56 | -22% YoY | 6 |
Latest Reports
BULLISH
Press
7/10
Altimmune presented new 48-week data from the IMPACT Phase 2b trial of pemvidutide in MASH at the EASL Congress 2026. Th
May 28, 2026
NEUTRAL
8-K
4/10
Altimmune reported Q1 2026 results with a net loss of $0.18 per share, narrower than the $0.26 loss in Q1 2025, but the
May 13, 2026
NEUTRAL
PRESS-RELEASE
5/10
Altimmune reported Q1 2026 EPS of -$0.18, beating the -$0.25 consensus estimate by 28%, though revenue was $0 (vs $1K co
May 13, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $39.4M | ADD |
| STATE STREET CORP | $22.0M | ADD |
| VANGUARD CAPITAL MANAGEMENT LLC | $17.4M | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $16.6M | — |
| MARSHALL WACE, LLP | $12.4M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 1, 2026 | SAYARE MITCHEL | A | $0.00 |
| May 1, 2026 | GILL JOHN | A | $0.00 |
| May 1, 2026 | Hodges Philip | A | $0.00 |
| May 1, 2026 | Pisano Wayne | A | $0.00 |
| May 1, 2026 | Schafer Klaus | A | $0.00 |
Reddit Sentiment
33°
Cool
Bearish
Neutral
Bullish
50 institutional holders with $174.4M total value (56,670,507 shares) as of 2026-Q1. Top holders: BlackRock,, STATE, VANGUARD. Net buying activity: 19 institutions added/increased vs 6 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 12,795,277 | $39.4M | 22.6% | ADD +31.9% |
| 2 | STATE STREET CORP | 7,145,550 | $22.0M | 12.6% | ADD +39.6% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 5,658,049 | $17.4M | 10.0% | — |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 5,382,002 | $16.6M | 9.5% | — |
| 5 | MARSHALL WACE, LLP | 4,017,901 | $12.4M | 7.1% | DOUBLED +335.4% |
| 6 | Alyeska Investment Group, L.P. | 2,644,600 | $8.1M | 4.7% | — |
| 7 | TWO SIGMA INVESTMENTS, LP | 2,478,900 | $7.6M | 4.4% | TRIM -36.6% |
| 8 | Nuveen, LLC | 2,334,601 | $7.2M | 4.1% | ADD +87.6% |
| 9 | GOLDMAN SACHS GROUP INC | 1,350,649 | $4.2M | 2.4% | — |
| 10 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,325,956 | $4.1M | 2.3% | — |
| 11 | DIMENSIONAL FUND ADVISORS LP | 1,045,926 | $3.2M | 1.8% | DOUBLED +268.7% |
| 12 | VANGUARD FIDUCIARY TRUST CO | 869,318 | $2.7M | 1.5% | — |
| 13 | MORGAN STANLEY | 775,258 | $2.4M | 1.4% | TRIM -43.0% |
| 14 | D. E. Shaw & Co., Inc. | 727,001 | $2.2M | 1.3% | DOUBLED +272.8% |
| 15 | FMR LLC | 673,964 | $2.1M | 1.2% | ADD +26.7% |
| 16 | Point72 Asset Management, L.P. | 665,289 | $2.0M | 1.2% | — |
| 17 | SCHRODER INVESTMENT MANAGEMENT GROUP | 667,837 | $1.9M | 1.1% | ADD +42.4% |
| 18 | BANK OF AMERICA CORP /DE/ | 570,203 | $1.8M | 1.0% | ADD +48.6% |
| 19 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 561,400 | $1.7M | 1.0% | — |
| 20 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 555,000 | $1.7M | 1.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | ADD | 9,704,298 | 12,795,277 | +31.9% | $39.4M | 2026-Q1 |
| STATE STREET CORP | ADD | 5,119,703 | 7,145,550 | +39.6% | $22.0M | 2026-Q1 |
| MARSHALL WACE, LLP | DOUBLED | 922,777 | 4,017,901 | +335.4% | $12.4M | 2026-Q1 |
| Nuveen, LLC | ADD | 1,244,211 | 2,334,601 | +87.6% | $7.2M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | 283,703 | 1,045,926 | +268.7% | $3.2M | 2026-Q1 |
| MORGAN STANLEY | TRIM | 1,359,885 | 775,258 | -43.0% | $2.4M | 2026-Q1 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | ADD | 469,013 | 667,837 | +42.4% | $1.9M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 383,783 | 570,203 | +48.6% | $1.8M | 2026-Q1 |
| Baird Financial Group, Inc. | ADD | 119,440 | 237,522 | +98.9% | $731.6K | 2026-Q1 |
| RHUMBLINE ADVISERS | ADD | 121,513 | 155,671 | +28.1% | $479.5K | 2026-Q1 |
| Grantham, Mayo, Van Otterloo & Co. LLC | TRIM | 172,559 | 126,389 | -26.8% | $389.3K | 2026-Q1 |
| DEUTSCHE BANK AG\ | ADD | 79,940 | 124,516 | +55.8% | $383.5K | 2026-Q1 |
| Brevan Howard Capital Management LP | TRIM | 114,128 | 78,403 | -31.3% | $241.5K | 2026-Q1 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | ADD | 52,566 | 77,292 | +47.0% | $234.8K | 2026-Q1 |
| MetLife Investment Management, LLC | ADD | 38,193 | 72,213 | +89.1% | $222.4K | 2026-Q1 |
| CANADA PENSION PLAN INVESTMENT BOARD | ADD | 30,000 | 53,300 | +77.7% | $164.2K | 2026-Q1 |
| ExodusPoint Capital Management, LP | DOUBLED | 11,921 | 48,619 | +307.8% | $149.7K | 2026-Q1 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | ADD | 27,596 | 34,763 | +26.0% | $107.1K | 2026-Q1 |
| BLAIR WILLIAM & CO/IL | TRIM | 56,434 | 28,223 | -50.0% | $86.9K | 2026-Q1 |
| VOYA INVESTMENT MANAGEMENT LLC | ADD | 13,690 | 21,011 | +53.5% | $64.7K | 2026-Q1 |
| GROUP ONE TRADING LLC | NEAR_EXIT | 31,372 | 6,695 | -78.7% | $20.6K | 2026-Q1 |
| Mirae Asset Global Investments Co., Ltd. | ADD | 5,070 | 6,532 | +28.8% | $20.1K | 2026-Q1 |
| CWM, LLC | ADD | 3,082 | 4,519 | +46.6% | $13.9K | 2026-Q1 |
| PNC FINANCIAL SERVICES GROUP, INC. | TRIM | 2,412 | 1,552 | -35.7% | $4.8K | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | 49,879 | 92,512 | +85.5% | $285.00 | 2026-Q1 |
13 unique insiders with 26 transactions. Net insider value: $198.4K ($198.4K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 1, 2026 | SAYARE MITCHEL | Director | AWARD | 48,800 | — | — |
| May 1, 2026 | GILL JOHN | Director | AWARD | 48,800 | — | — |
| May 1, 2026 | Hodges Philip | Director | AWARD | 48,800 | — | — |
| May 1, 2026 | Pisano Wayne | Director | AWARD | 48,800 | — | — |
| May 1, 2026 | Schafer Klaus | Director | AWARD | 48,800 | — | — |
| May 1, 2026 | Jorkasky Diane | Director | AWARD | 48,800 | — | — |
| May 1, 2026 | Sohn Catherine A. | Director | AWARD | 48,800 | — | — |
| May 1, 2026 | Lawver Teri L | Director | AWARD | 48,800 | — | — |
| Apr 6, 2026 | GILL JOHN | Director | BUY | 9,200 | $3.41 | $31.3K |
| Apr 1, 2026 | Durso Jerome Benedict | President and CEO | BUY | 15,000 | $3.14 | $47.1K |
| Apr 1, 2026 | WEAVER GREGORY L | Chief Financial Officer | BUY | 10,000 | $3.15 | $31.5K |
| Mar 6, 2026 | WEAVER GREGORY L | Chief Financial Officer | BUY | 5,000 | $3.54 | $17.7K |
| Mar 6, 2026 | Durso Jerome Benedict | President and CEO | BUY | 20,000 | $3.54 | $70.8K |
| Feb 26, 2026 | Roberts M Scot | Chief Scientific Officer | AWARD | 95,430 | — | — |
| Feb 26, 2026 | Roberts M Scot | Chief Scientific Officer | AWARD | 222,670 | — | — |
| Feb 26, 2026 | WEAVER GREGORY L | Chief Financial Officer | AWARD | 259,000 | — | — |
| Feb 26, 2026 | WEAVER GREGORY L | Chief Financial Officer | AWARD | 111,000 | — | — |
| Feb 2, 2026 | Roberts M Scot | Chief Scientific Officer | EXERCISE | 7,775 | — | — |
| Feb 2, 2026 | Roberts M Scot | Chief Scientific Officer | TAX W/H | 2,329 | $5.55 | $12.9K |
| Jan 31, 2026 | Roberts M Scot | Chief Scientific Officer | AWARD | 5,567 | $3.07 | $17.1K |
| Jan 31, 2026 | Jordt Raymond M | Chief Business Officer | AWARD | 4,571 | $3.07 | $14.0K |
| Jan 31, 2026 | Garg Vipin K | Director | AWARD | 6,926 | $3.07 | $21.3K |
| Jan 30, 2026 | Roberts M Scot | Chief Scientific Officer | EXERCISE | 9,275 | — | — |
| Jan 30, 2026 | Roberts M Scot | Chief Scientific Officer | TAX W/H | 2,859 | $5.60 | $16.0K |
| Jan 30, 2026 | Garg Vipin K | Director | EXERCISE | 26,775 | — | — |
| Jan 30, 2026 | Garg Vipin K | Director | TAX W/H | 11,632 | $5.60 | $65.1K |
10 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 9 neutral. Avg impact: 4.4/10.
NEUTRAL
8-K
4/10
Altimmune reported Q1 2026 results with a net loss of $0.18 per share, narrower than the $0.26 loss
May 13, 2026
NEUTRAL
PRESS-RELEASE
5/10
Altimmune reported Q1 2026 EPS of -$0.18, beating the -$0.25 consensus estimate by 28%, though reven
May 13, 2026
NEUTRAL
PRESS-RELEASE
2/10
Altimmune announced it will report Q1 2026 financial results on May 13, 2026. The press release cont
May 6, 2026
NEUTRAL
8-K
5/10
Altimmune is raising $211.5 million through a public offering of 64.25 million shares of common stoc
Apr 24, 2026
NEUTRAL
424B5
5/10
Altimmune is raising $211.5 million through a public offering of 64.25 million shares of common stoc
Apr 24, 2026
NEUTRAL
424B5
5/10
Altimmune is conducting a follow-on public offering of common stock, pre-funded warrants, and common
Apr 22, 2026
NEUTRAL
CLUSTER
3/10
Three corporate insiders at Altimmune, Inc. purchased shares in the open market over a 7-day period,
Apr 6, 2026
NEUTRAL
CLUSTER
4/10
Two top executives at Altimmune — the CEO and CFO — collectively purchased $79K worth of stock in ea
Apr 1, 2026
NEUTRAL
CLUSTER
4/10
Altimmune's CEO and CFO collectively purchased $88,490 worth of shares in open-market transactions o
Mar 9, 2026
BULLISH
8-K
7/10
Altimmune reported financial results for Q4 and full year 2025, highlighted by a 7% reduction in net
Mar 5, 2026
BULLISH
7/10
Altimmune presented new 48-week data from the IMPACT Phase 2b trial of pemvidutide in MASH at the EA
May 28, 2026
NEUTRAL
2/10
Altimmune announced management participation in upcoming investor conferences, a routine corporate e
May 27, 2026
BULLISH
6/10
Altimmune announced that its 48-week IMPACT Phase 2b data for pemvidutide in MASH has been selected
May 13, 2026
BEARISH
7/10
Altimmune announced the pricing of a public offering of common stock and pre-funded warrants, along
Apr 23, 2026
BULLISH
8/10
Altimmune reported its Q4 and full-year 2025 financial results, highlighted by a strengthened balanc
Mar 5, 2026
Current analyst consensus: Strong Buy (80% buy). Based on 15 analysts: 3 strong buy, 9 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$16.06 mean target
+515.2% upside
Strong Buy (1.60)
$2.50 Low
$28.00 High
| Metric | Value |
|---|---|
| Current Price | $2.61 |
| Target Low | $2.50 |
| Target Mean | $16.06 |
| Target Median | $18.00 |
| Target High | $28.00 |
| # Analysts | 9 |
| Recommendation | Strong Buy (1.60) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.16 | $-0.22 | $-0.10 | 40.7% | — | 6↑ 0↓ | $0.0B | -68.8% | 6 |
| Next Q 2026-09-30 |
$-0.18 | $-0.24 | $-0.11 | 15.9% | — | 6↑ 0↓ | $0.0B | -68.8% | 6 |
| Current FY 2026-12-31 |
$-0.74 | $-0.96 | $-0.52 | 26.0% | — | 6↑ 0↓ | $0.0B | -88.9% | 6 |
| Next FY 2027-12-31 |
$-0.90 | $-1.25 | $-0.56 | -21.9% | — | 6↑ 0↓ | $0.0B | -100.0% | 6 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.160 | |
| 7d ago | $-0.160 | |
| 30d ago | $0.000 | -0.160 |
| 60d ago | $-0.259 | +0.099 |
| 90d ago | $-0.283 | +0.123 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 18, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 14, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Mar 16, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 6, 2026 | B. Riley Securities | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 9 | 3 | 0 | 0 | 80% | |
| May 1, 2026 | 3 | 9 | 3 | 0 | 0 | 80% | |
| Apr 1, 2026 | 3 | 9 | 2 | 1 | 0 | 80% | |
| Mar 1, 2026 | 3 | 9 | 2 | 1 | 0 | 80% | |
| Feb 1, 2026 | 3 | 9 | 2 | 1 | 0 | 80% | |
| Jan 1, 2026 | 3 | 8 | 2 | 1 | 0 | 79% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
33°
Cool
Bearish
Neutral
Bullish
2 mentions
0 bullish
2 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 26, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 26, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
Earnings play
▲ 1
💬 1
⚡ 0.5
Jun 3, 2026
short_volume
Short Volume: ALT — 58.4% short (1.0M / 1.6M)
Short: 951,954 | Exempt: 0 | TRF Vol: 1,629,206 | Short Ratio: 58.4% | Off-exchange volume (dark pool + OTC)
May 28, 2026
fda
Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026
<p align="center"><em>“Best of EASL” oral presentation highlights meaningful reductions in triglycerides, cholesterol, and blood pressure, along with
May 27, 2026
fda
Altimmune to Participate in Upcoming Investor Conferences
<p align="left">GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=7-Z5xYGuWSfHFnGLTQMosLYNgxTW
May 19, 2026
Clinical Trial
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
Phase Phase 2 — COMPLETED
May 13, 2026
earnings
Altimmune Announces First Quarter 2026 Financial Results and Business Update
<p align="center"><em>Initiation of PERFORMA Phase 3 MASH trial planned for second half 2026</em></p>
May 13, 2026
fda
Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026
<p align="center"><em>Abstract presenting 48-week IMPACT Phase 2b efficacy and safety data selected for inclusion in “Best of EASL 2026” by EASL</em><
May 13, 2026
earnings_calendar
ALT Q1 2026 Earnings Before Market Open — 2026-05-13
May 7, 2026
earnings_calendar
ALT Q1 2026 Earnings Before Market Open — 2026-05-07
May 6, 2026
earnings
Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
<p align="justify">GAITHERSBURG, Md., May 06, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=S7Fb0rQYRHd89JAHkwDYAC-r2
Apr 30, 2026
short_volume
Short Volume: ALT — 55.4% short (1.9M / 3.4M)
Short: 1,905,071 | Exempt: 0 | TRF Vol: 3,436,496 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)
Apr 29, 2026
short_volume
Short Volume: ALT — 63.5% short (1.6M / 2.5M)
Short: 1,616,710 | Exempt: 8,346 | TRF Vol: 2,546,964 | Short Ratio: 63.5% | Off-exchange volume (dark pool + OTC)
Apr 27, 2026
short_volume
Short Volume: ALT — 58.4% short (1.8M / 3.0M)
Short: 1,764,406 | Exempt: 161 | TRF Vol: 3,018,994 | Short Ratio: 58.4% | Off-exchange volume (dark pool + OTC)
Apr 24, 2026
short_volume
Short Volume: ALT — 60.9% short (3.9M / 6.4M)
Short: 3,894,595 | Exempt: 216,639 | TRF Vol: 6,399,570 | Short Ratio: 60.9% | Off-exchange volume (dark pool + OTC)
Apr 23, 2026
offering
Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities
<p align="justify">GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=eyrgv02seuEx013pn1dsfDa
Apr 23, 2026
short_volume
Short Volume: ALT — 63.7% short (10.0M / 15.7M)
Short: 9,998,203 | Exempt: 599,761 | TRF Vol: 15,704,910 | Short Ratio: 63.7% | Off-exchange volume (dark pool + OTC)
Apr 22, 2026
offering
Altimmune Announces Proposed Underwritten Public Offering of Securities
<p align="justify">GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=NueRmSZp_xj1mwkEhZduwwq